Abstract: The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.

Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.

Abstract: The disclosure relates to a substrate comprising a micro- or nanostructured periodic array comprised of a plurality of anisotropic metallic micro- or nanostructures, wherein each of the plurality of nanostructures induce an average maximum and substantially uniform plasmonic field greater than 108 across the substrate; a plurality of Raman-active linker molecules directly bound to the metallic micro- or nanostructures; and a plurality of capture molecules directly bound to the Raman-active linker molecules. The disclosure also relates to systems, devices, and methods that use the substrates to determine the concentration of various analytes.

Abstract: A continuum device/manipulator includes a first flexible tube, a low melting point (LMP) alloy disposed within the first flexible tube, and a temperature adjustment element that applies heat or cooling to change a phase of the LMP alloy. Changing the phase of the LMP alloy controls a flexibility of the first flexible tube.

Abstract: Compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other cancer therapies that achieve the same or similar therapeutic effect.

Abstract: An extracellular matrix (ECM) mixture and ECM scaffolds made with same are disclosed. The ECM mixture can comprise from about 5% to about 85% by weight of ECM material and from about 15% to about 95% by weight of a polymer material, such as, but not limited to, a biodegradable polyester. The presently disclosed anatomically-shaped porous ECM scaffolds can be formed, for example, using a three-dimensional (3D) printing process, an injection molding process, or any other process.

Abstract: A hydropersulfide precursor compound having the formula (I): formula (I) as defined in the specification. A process for preparing the hydropersulfide precursor, and a method of using the precursor to generate hydropersulfide are also described.

Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.

Abstract: A calibration platform may obtain measurements for aligning a real-world coordinate system and a display coordinate system. For example, the calibration platform may display, via an optical see-through head-mounted display (OST-HMD), a three-dimensional virtual object and receive, from a positional tracking device, information that relates to a current pose of a three-dimensional real-world object to be aligned with the three-dimensional virtual object. The calibration platform may record a three-dimensional position of a plurality of points on the three-dimensional real-world object based on the current pose of the three-dimensional real-world object, based on an indication that the plurality of points on the three-dimensional real-world object respectively corresponds with a plurality of points on the three-dimensional virtual object.

Abstract: Methods and systems for growing thin films via molecular-beam epitaxy (MBE) on substrates are provided. The methods and systems utilize a thermally conductive backing plate including an infrared-absorbing coating (IAC) formed, for example, on one side of the thermally conductive backing plate to provide an asymmetric emissivity that absorbs infrared radiation (IR) on the side having the IRC and does not on the non-coated side of the thermally conductive backing plate (e.g., refractive metal or alloy). The asymmetric emissivity shields the thin film being deposited on a substrate from the IR during formation.

Abstract: A process for autonomous mechanical property testing of specimens on a build plate includes fabricating a plurality of the specimens on a build plate, wherein each of the specimens comprises an upper portion and a lower portion integral to the build plate. Each of the upper portions of the specimens on the build plate are sequentially engaged with an end effector on a terminal end of a multi-linked robotic arm, wherein the end effector is configured to engage the upper portion and apply a uni- or multi-modal load, wherein intermediate the end effector and the multi-linked robotic arm comprises a multi-axis load cell for measuring an applied load. The process further includes autonomously calculating one or more mechanical properties from the applied load.

Abstract: Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

Abstract: Contaminate-sequestering coatings including a network of hydrolyzed silane compounds including a plurality of thiol functional groups, a plurality of fluorinated functionalities, or both are provided. The contaminate-sequestering coatings may sequester one or more per- and polyfluoroalkyl substances (PFAS), heavy metals, biological species or any combination thereof. Methods of functionalizing a substrate surface with contaminate-sequestering functionalities that sequester one or more PFAS, heavy metals, or both are also provided. Methods of removing contaminants from contaminate-containing liquids, and devices including the contaminate-sequestering coatings are also provided.

Abstract: A device may receive images of a patient, and may perform segmentation of surfaces on the images to create a 3D model. The device may identify normal tissue regions and atrial fibrosis (AF) regions in the 3D model, and may divide the 3D model into the normal tissue regions and the AF regions. The device may assign first cell and tissue properties to the normal tissue regions, and may assign second cell and tissue properties to the AF regions. The device may perform simulations on the normal tissue regions and the AD regions, based on the first and second cell and tissue properties, to generate simulation results, and may extract first features from the simulation results. The device may extract second features from the images, and may process the first and second features, with a model, to select a feature that is predictive of atrial fibrillation recurrence.

Abstract: An appliance for monitoring blood flow is provided. The appliance includes a plurality of spatially separated acousteomic sensors for auscultation detection of a patient; a hardware processor and a non-transitory computer-readable medium that stores a trained computer model for modeling a function of a healthy heart for analyzing the acousteomic signals; and a transmitter that transmits the acousteomic signals from the plurality of acousteomic sensors.

Abstract: A body mountable robot may include a set of stages disposed in a parallel configuration. The body mountable robot may include a set of actuating joints, wherein an actuating joint, of the set of actuating joints, is configured to rotate with respect to a corresponding stage of the set of stages. The body mountable robot may include at least one actuator, wherein the at least one actuator is configured to actuate at least one actuating joint of the set of actuating joints. The body mountable robot may include a set of scissor mechanisms, wherein a scissor mechanism, of the set of scissor mechanisms, that is coupled to the actuating joint, is supported by the corresponding stage, and wherein the scissor mechanism is configured to translate with respect to the corresponding stage.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.

Abstract: The present invention is directed toward a system and method for STED nanography, which reduces background noise. To remove background noise from a STED image, the polarization of the STED beam is altered from that used to obtain the original image. A polarized image is obtained. This polarized image can then be subtracted from the original image to remove noise inherent to the image.

Abstract: A strategy using reverse phosphoramidites for synthesizing oligonucleotides containing Fapy·dG is disclosed.

Abstract: A substantially metallic magnetic resonance Imaging (MRI)-tracked injection needle device is disclosed. The magnetic resonance Imaging (MRI)-tracked injection needle device includes a luer syringe; an electrical connector that is at least partially housed in an interior space of a distal end of the luer syringe; an electrical adaptor coupled to the electrical connector; and an injection needle comprising a shaft having a needle distal end and a needle proximal end, the shaft comprising concentric metal tubes comprising an inner metal tube and an outer metal tube, the needle proximal end coupled to the electrical adaptor and the needle distal end comprising one or more tracking coils arranged between the inner metal tube and the outer metal tube.